论文部分内容阅读
目的 探讨乙肝特异性转移因子、肝康灵和左旋咪唑布剂联合应用，对无症状ＨＢＶ 携带者血清细胞因子的影响。方法 用ＥＬＩＳＡ 法测定了治疗Ⅰ组（３８ 例大三阳） 、治疗Ⅱ组（９７ 例小三阳） 、对照Ⅰ（２８例大三阳） 以及对照Ⅱ组（５５ 例小三阳） 血清可溶性白细胞介素２ 受体（ｓｏｌｕｂｌｅ ｉｎｔｅｒｌｅｕｋｉｎ － ２ ｒｅｃｅｐｔｏｒ，ＳＩＬ－２Ｒ） 和肿瘤坏死因子（ｔｕｍｏｒ ｎｅｃｒｏｓｉｓｆａｃｔｏｒ－ α，ＴＮＦ－ α） ．结果 结疗Ⅰ、Ⅱ组血清ＳＩＬ－ ２Ｒ 水平治疗前为３４４ ．９４Ｕ／ｍｌ、３０６ ．１１Ｕ／ｍｌ，治疗后下降至２８５ ．２０Ｕ／ｍｌ、２４７ ．５５Ｕ／ｍｌ，其差异均有显著性（Ｐ＜ ０ ．０５） ；血清ＴＮＦ－ α水平由治疗前３ ．６１ｎｇ／ｍｌ、３ ．４４ｎｇ／ｍｌ 下降至治疗后的２ ．０４ｎｇ／ｍｌ、２ ．０７ｎｇ／ｍｌ，其差异均有显著性（Ｐ＜ ０ ．０５） 。而对照Ⅰ、Ⅱ组治疗前后比较则无此等变化（Ｐ＜ ０ ．０５） 。提示 乙肝特异性转移因子等三种药物物联用，对无症状ＨＢＶ 细胞因子有明显的免疫调节作用。
Objective To investigate the effects of hepatitis B specific transfer factor, heparin and levamisole on serum cytokines in asymptomatic HBV carriers. Methods Serum soluble interleukin (IL-6) was measured by enzyme-linked immunosorbent assay (ELISA) in the treatment group Ⅰ (38 cases of Danshen Yang), treatment group Ⅱ (97 cases of Xiaosanyang), control Ⅰ Soluble interleukin - 2 receptor (SIL - 2R) and tumor necrosis factor - α (TNF - α). Results The serum levels of SIL-2R in group Ⅰ and group Ⅱ before treatment were 344. 94U / ml, 306. 11U / ml, down to 285 after treatment. 20U / ml, 247. 55U / ml, the difference was significant (P <0 .05); serum TNF-α levels from before treatment 3. 61ng / ml, 3. 44ng / ml to 2 after treatment. 04ng / ml, 2. 07ng / ml, the difference was significant (P <0 .05). The control Ⅰ, Ⅱ group before and after treatment compared with no such change (P <0 .05). Prompt hepatitis B-specific transfer factor combination of three drugs, asymptomatic HBV cytokines have a significant immunomodulatory effect.